Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Cisco Systems

Diamondback Energy

Nokia

Pfizer

Williams

At this writing, current inflation rate is 3% over the past 12 months. That's the reading as of the end of June.

7 High-Yield Dividend Stocks Beating Inflation

DaVita

Renal Denervation Devices Market Size, Share & Trends Analysis Report By Technology (Radiofrequency-based, Ultrasound-based, Micro-infusion-based, Others), By End User (Hospitals & Clinics, Ambulatory surgery centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032 Renal Denervation Devices Market Size, Share & Trends Analysis Report By Technology (Radiofrequency-based, Ultrasound-based, Micro-infusion-based, Others), By End User (Hospitals & Clinics, Ambulatory surgery centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Renal Denervation Devices Market Expected to Reach USD 387 Million by 2032 with a Remarkable 37.2% CAGR, According to Straits Research

The medical-device specialist habitually declares dividend raises. This year's model is quite modest, though, so buyer beware.

How Much Will Medtronic Pay Out in Dividends This Year?

Medtronic is a global leader in medical therapies, with portfolios in cardiovascular, neuroscience, medical surgical, and diabetes segments. My investment thesis is based on market leadership, a robust pipeline, and a strong balance sheet for M&A, with a bullish outlook on future growth. MDT has underperformed in recent years, but with earnings growth and a strong pipeline, I consider shares to be cheap.

Medtronic: An Out Of Favor Healthcare Stock With A Pulse On Profit Potential

Agree Realty

Realty Income Corp

Medtronic is a giant medical technology company that has raised its dividend payout for 47 years consecutive years. As a successful net lease REIT, Agree Realty has raised its dividend payout by 34% over the past five years.

3 High-Yield Dividend Stocks to Buy in the 2nd Half of 2024 and Hold at Least a Decade

Johnson & Johnson

Johnson & Johnson and Medtronic are healthcare leaders that have faced their share of issues in recent years. Still, both companies have the innovative capabilities and expertise to succeed in the industry in the long run.

2 Healthcare Stocks to Buy Hand Over Fist This Month

Abbott Labs

Gilead Sciences

HCA Healthcare

Novartis

Tenet Healthcare

Over the years, especially the past three, I have become more cautious about the technology sector's blatant overvaluation. Nevertheless, it is difficult to ignore the capabilities of companies such as Nvidia (NASDAQ: NVDA ) and their innovative solutions for AI.

The 7 Most Undervalued Healthcare Stocks to Buy in July 2024

Recursion Pharmaceuticals

While the pairing of artificial intelligence and healthcare may sound like something straight out of a science fiction movie, there are several avenues through which the high-speed data processing offered by AI can improve patient outcomes. From more precise diagnosis to pandemic modeling, the large-scale algorithmic models we call AI can help the world of medicine immensely.

3 Healthcare Stocks Injecting AI for Big Gains

Bristol-Myers

Magna International

As the second half of 2024 unfolds, main Wall Street indices are reaching new highs. The Nasdaq 100 index soared more than 20% year-to-date, and the S&P 500 saw an all-time high with a 16% surge.

3 Undervalued Stocks Ready for a Breakout This Summer

Cigna

Merck

Toll Brothers

Cigna, Merck, Toll Brothers, Medtronic could see shares gain after proving their earnings growth remains strong.

4 Cheap Stocks to Buy Ahead of Earnings

Dublin, July 09, 2024 (GLOBE NEWSWIRE) -- The "Nasal Packing Devices Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering.

Nasal Packing Devices: Global Market Forecasts from 2024 to 2029 Featuring Strategic Analysis of Meril Life, Anthony Products, Medtronic, Entsho, and Innovia Medical Among Others

Buy-and-hold stocks don't have to be boring. Often, investors looking for buy-and-hold stocks see recommendations centered around what can be called charitably value traps.

7 ‘Buy and Hold Forever' Stocks for Lasting Riches

Anheuser-Busch InBev

Altria

Philip Morris

A Lower-risk portfolio can be created by buying durable companies with long track records of rewarding shareholders at attractively low prices. Overpaying for a stock can lead to outsized risks, so it's important to separate price from value and company from stock. Medtronic and Altria are dividend aristocrat value stocks trading far below historical norms, offering income and potential for capital gains.

I'm Buying Dividend Aristocrats With Up To 8.5% Yield

iRobot

Rockwell Automation

Robotics is the core of automation in a variety of business sectors. In this day and age, with the demand for and proliferation of artificial intelligence- and machine learning-based technologies, the robotics sector could experience a real boom.

3 Robotics Stocks to Sell in July Before They Crash & Burn

UiPath

The remarkable advancements in automation, powered by robotics, have put several robotics stocks to buy on investors' radar.  In recent years, the mushrooming power, utility and functionality of artificial intelligence have accelerated the use of robotics across several industries.

3 Robotics Stocks to Buy on the Dip: Summer 2024

Comcast

U.S. Bancorp

The highlighted companies are currently out of favor with the market, offering an opportunity to invest in undervalued stocks with high yields. Medtronic is a leader in medical devices, U.S. Bancorp is the largest regional bank, and Comcast is a dominant player in broadband and entertainment. Each stock has investment grade credit ratings, growing dividends, and projected 5-year PEG ratios below historical averages, making them attractive buys.

Yielding An Average Of 4%, My Top 3 Buys For July

Steel Dynamics

AMERCO

If this year's market volatility has you feeling uneasy, you're not alone. The overvaluation of many tech stocks has created a challenging environment, but plenty of affordable, undervalued blue-chip stocks can provide the stability your portfolio needs.

Blue-Chip Fire Sale: 3 Stocks the Market is Dead Wrong About

Medtronic's (MDT) stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.

Medtronic Loses 5% in a Month: What's Next for MDT Investors?

British American Tobacco

Campbell Soup

Dow Inc

Duke Energy

Kinder Morgan

Polaris

PNC Financial Services

SPDR S&P 500 ETF Trust

Sempra Energy

Toronto-Dominion Bank

Verizon

Morningstar published 10 Best Value Stocks to Buy for the Long Term, undervalued blue-chip stocks with low price to fair value. Valuation and future return of each stock analyzed, compared to the S&P 500, Bristol-Myers has the highest potential rate of return. In comparison to Morningstar's 10 Best Value Stocks with 10 Best Dividend Stocks, Bristol-Myers stands out as undervalued with a high potential return.

Going Beyond Morningstar's 10 Best Value Stocks List

Albemarle

Franklin Resources

C.H. Robinson Worldwide

Clorox

Hormel Foods

McCormick

Nordson

ProShares S&P 500 Dividend Aristocrats ETF

Stanley Black & Decker

Target

The ProShares S&P 500 Dividend Aristocrats ETF continues its positive run in 2024, posting a gain of 1.45% in May. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 35 months of tracking these strategies, two strategies are outperforming NOBL, while 1 remain relatively close.

My Best Dividend Aristocrats For July 2024

News for Medtronic Stock (MDT)